Dr. Mazyar Shadman, MD, MPH

Dr. Shadman practices at Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center.

Dr. Shadman's NPI, 1750554077, was assigned on April 8, 2008. Dr. Shadman holds Washington license MD60222800.

Dr. Shadman's primary practice is Fred Hutchinson Cancer Center, at 825 Eastlake Avenue East, Seattle, WA 98109.

Dr. Shadman's primary practice is Fred Hutchinson Cancer Center in Seattle, Washington, part of Fred Hutchinson Cancer Center. The medical group on file is UW Physicians.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shadman practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shadman's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Shadman is licensed in Washington.

CMS data shows 319 Medicare services from Dr. Shadman across 4 procedure codes in 2024, for 162 Medicare patients. Medicare paid $25,030 for them. Every service was in an office.

CMS counts 162 Medicare patients who saw Dr. Shadman in 2024. The largest group is 65 to 74, with 92 patients. 56% of them have high blood pressure, and 54% have high cholesterol. Their average risk score is 2.25, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shadman's median patient age at 70, with 34% women.

In 2024, Dr. Shadman wrote 85 Medicare Part D claims for 27 patients. 41% of them were for generic drugs. CMS names the drug for 21 of them, across 1 drug with 11 or more claims each, at $298,838 in total drug cost. In 2023, CMS named 36 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 94 out of 100 for Dr. Shadman for performance year 2024, reported through an alternative payment model (APM). Dr. Shadman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shadman as offering telehealth.

Dmand AI links 172 papers to Dr. Shadman, published from 2011 to 2025. 2024 was the busiest year, with 26. The most frequent topics are Leukemia, Lymphocytic, Chronic, B-Cell, Antineoplastic Combined Chemotherapy Protocols and Immunotherapy, Adoptive. Dr. Shadman has published most often in Blood Adv. Dr. Shadman's most frequent co-authors are Chaitra Shankar Ujjani, MD, Ajay Kumar Gopal and Brian Gerald Till, MD.

Dmand AI links Dr. Shadman to 6 clinical trials, 2 of them phase 3 studies. 4 are still active or recruiting. Conditions studied include Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, B-Cell and Lymphoma, Non-Hodgkin. BeiGene sponsors the most, 2.

CMS Open Payments shows 293 general payments to Dr. Shadman from 30 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 86% of the total. Abbvie Inc. paid the most, $42,117. It also lists 24 research payments totaling $12,548 from 2020 to 2025.